POLR3A and systemic sclerosis: In a recent study focused on SSc patients with autoantibodies against POLR3A in whom cancer does not emerge, we found that patients who also had autoantibodies against the large subunit of RNA polymerase I (RPA194) had a much lower incidence of cancer than those with antibodies against POLR3A alone (16).